Familial juvenile hyperuricemic nephropathy (FJHN) is a rare and
difficult to manage disease. Early diagnosis, early treatment with
allopurinol and regular follow up can ameliorate the long-term
progression to end-stage renal disease. We report a 7-year-old,
asymptomatic patient with anemia, reduced renal function and
hyperuricemia. Genetic screening played a crucial role in establishing
the diagnosis.
A 7-year-old girl was referred to our clinic due to
abnormal renal function tests noted in laboratory work-up for assessment
of chronic anemia. Her past medical history was otherwise unremarkable.
She was the fourth child of her family and there was no family history
of renal pathology, except for diabetic nephropathy in the grandfather.
Upon admission, her blood pressure was 123/93 mmHg (99th centile),
weight 24 kg (25th centile) and height 127.5 cm (75th centile). Systemic
examination was normal. Laboratory examination revealed increased blood
urea nitrogen (BUN) (61 mg/dL), serum creatinine (1.23 mg/dL) and serum
uric acid (8.52 mg/dL). The hematocrit was 32.3%, hemoglobin 10.8 g/dL,
MCV 79.7 fL, MCH 26.7 pg and MCHC 33.5. Rest of the laboratory results
were within normal limits. The glomerular filtration rate (GFR) was
calculated as 65.5 mL/min/1.73 m2 (stage 2 chronic renal disease).
Fractional excretion of uric acid was 6 % (normal range 18±5%). Urine
analysis results showed no abnormality. On sonographic examination,
right kidney length was 7 cm and left kidney length 6.9 cm (25th centile),
with increased cortical echogenicity of both kidneys, suggestive of
parenchymal renal disease. Further imaging with mercaptoacetyltriglycine
(MAG3) diuretic renogram indicated a moderate loss in renal function of
both kidneys.
The laboratory and imaging findings were consistent
with renal cortical necrosis. However, there was no previous medical
history indicating a causative factor such as, chronic lead nephropathy
or exposure to toxins and drugs for above findings. Moreover, the
increased level of blood uric acid combined with its reduced fractional
renal excretion could not be attributed only to the degree of renal
failure. Thus, the possible diagnosis seemed to be genetic, most likely
FJHN. In order to confirm the diagnosis, genetic testing was carried
out. Mutation analysis of Uromodulin, the gene known to encode
Tamm-Horsfall protein, revealed an in-frame deletion between nucleotides
668-767 and a replacement of conservative Glu 188 by an irrelevant
valine, leading to a defective protein with 2 of 24 consecutive cysteine
residues being removed. Cysteine residues are thought to be crucial in
the cross-linking of the protein. Mutations involving them alter its
tertiary structure and are commonly found in autosomal dominant
tubulointerstitial kidney diseases (ADTKD) such as FJHN [1]. Our patient
progressed to end stage renal failure at the age of 12 years. Her
anemia, which was normocytic, normochromic was attributed to the chronic
renal disease and was treated with erythropoetin. With the exception of
renin (REN) gene-related ADTKD and nephronophthisis, anemia is
not considered a typical finding of the condition [2]. The patient
received a cadaver kidney transplant after 1 year of peritoneal
dialysis, since the disease does not recur in the graft.
Familial juvenile hyperuricemic nephropathy is a rare
genetic disease which falls into the category of ADTKD [2]. It is
characterized by reduced renal excretion of urate, early onset
hyperuricemia and slow progression to chronic end-stage renal disease.
The exact pathophysiologic mechanism of the disease is not yet fully
understood. It is presumed that mutations in the gene encoding Tamm-Horsfall
protein, the most abundant protein in the urine, induce tubular
dysfunction and subsequent uric acid retention [3,4]. FJHN is an
autosomal-dominant disorder but this particular case did not have the
expected findings of chronic renal disease, early hyperuricemia and
episodes of gout [2]. Even in this case, ADTKD should still be
considered in the differential diagnosis, as these may be de novo
cases or with wrong diagnoses in other relatives [5,6]. Attempts can be
made to select patients at risk of chronic kidney disease as a part of
appropriate genetic counseling, which aims to detect them and improve
their prognosis.
REFERENCES
1. Schäffer P, Gombos E, Meichelbeck K, Kiss A, Hart
PS, Bleyer AJ. Childhood course of renal insufficiency in a family with
uromodulin gene mutation. Pediatr Nephrol. 2010;25:1355-60.
2. Eckardt K-U, Alper SL, Antignac C, Bleyer AJ,
Chauveau D, Dahan K, et al. Autosomal dominant tubulointerstitial
kidney disease: diagnosis, classification, and management – A KDIGO
consensus report. Kidney Int.2015;88:676-83.
3. Liu M, Chen Y, Liang Y, Liu Y, Wang S, Hou P,
Zhang, et al. Novel UMOD mutations in familial juvenile
hyperuricemic nephropathy lead to abnormal uromodulin intracellular
trafficking. Gene. 2013;531:363-9.
4. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z,
Sandhu J, et al. Mutations of the UMOD gene are responsible for
medullary cystic kidney disease 2 and familial juvenile hyperuricaemic
nephropathy. J Med Genet. 2002;39:882-92.
5. Malakoutian T, Amouzegar A, Vali F, Asgari M,
Behnam B. First Report of familial juvenile hyperuricemic nephropathy
(FJHN) in Iran caused by a novel de novo mutation (E197X) in UMOD. J Mol
Genet Med. 2016;10:218.
6. Wheeler E, Thomas S. Diagnosis and long-term
management of uromodulin kidney disease. Cureus.2019;11:e4270.